These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
282 related articles for article (PubMed ID: 23217195)
1. A bivalent recombinant protein inactivates HIV-1 by targeting the gp41 prehairpin fusion intermediate induced by CD4 D1D2 domains. Lu L; Pan C; Li Y; Lu H; He W; Jiang S Retrovirology; 2012 Dec; 9():104. PubMed ID: 23217195 [TBL] [Abstract][Full Text] [Related]
2. Characterization of Human Immunodeficiency Virus (HIV-1) Envelope Glycoprotein Variants Selected for Resistance to a CD4-Mimetic Compound. Anang S; Richard J; Bourassa C; Goyette G; Chiu TJ; Chen HC; Smith AB; Madani N; Finzi A; Sodroski J J Virol; 2022 Sep; 96(17):e0063622. PubMed ID: 35980207 [TBL] [Abstract][Full Text] [Related]
3. HIV-1 gp41-targeting fusion inhibitory peptides enhance the gp120-targeting protein-mediated inactivation of HIV-1 virions. Qi Q; Wang Q; Chen W; Du L; Dimitrov DS; Lu L; Jiang S Emerg Microbes Infect; 2017 Jun; 6(6):e59. PubMed ID: 28634358 [TBL] [Abstract][Full Text] [Related]
4. Anti-HIV-1 activity of cellulose acetate phthalate: synergy with soluble CD4 and induction of "dead-end" gp41 six-helix bundles. Neurath AR; Strick N; Jiang S; Li YY; Debnath AK BMC Infect Dis; 2002 Apr; 2():6. PubMed ID: 11983022 [TBL] [Abstract][Full Text] [Related]
5. A low-molecular-weight entry inhibitor of both CCR5- and CXCR4-tropic strains of human immunodeficiency virus type 1 targets a novel site on gp41. Murray EJ; Leaman DP; Pawa N; Perkins H; Pickford C; Perros M; Zwick MB; Butler SL J Virol; 2010 Jul; 84(14):7288-99. PubMed ID: 20427524 [TBL] [Abstract][Full Text] [Related]
6. The C4 region as a target for HIV entry inhibitors--NMR mapping of the interacting segments of T20 and gp120. Moseri A; Biron Z; Arshava B; Scherf T; Naider F; Anglister J FEBS J; 2015 Dec; 282(24):4643-57. PubMed ID: 26432362 [TBL] [Abstract][Full Text] [Related]
8. Identification of a human protein-derived HIV-1 fusion inhibitor targeting the gp41 fusion core structure. Chao L; Lu L; Yang H; Zhu Y; Li Y; Wang Q; Yu X; Jiang S; Chen YH PLoS One; 2013; 8(5):e66156. PubMed ID: 23741527 [TBL] [Abstract][Full Text] [Related]
9. Soluble CD4 and CD4-mimetic compounds inhibit HIV-1 infection by induction of a short-lived activated state. Haim H; Si Z; Madani N; Wang L; Courter JR; Princiotto A; Kassa A; DeGrace M; McGee-Estrada K; Mefford M; Gabuzda D; Smith AB; Sodroski J PLoS Pathog; 2009 Apr; 5(4):e1000360. PubMed ID: 19343205 [TBL] [Abstract][Full Text] [Related]
10. A novel chimeric protein-based HIV-1 fusion inhibitor targeting gp41 glycoprotein with high potency and stability. Pan C; Cai L; Lu H; Lu L; Jiang S J Biol Chem; 2011 Aug; 286(32):28425-34. PubMed ID: 21690094 [TBL] [Abstract][Full Text] [Related]
11. Synergistic Effect by Combining a gp120-Binding Protein and a gp41-Binding Antibody to Inactivate HIV-1 Virions and Inhibit HIV-1 Infection. Wang X; Cao M; Wu Y; Xu W; Wang Q; Ying T; Lu L; Jiang S Molecules; 2021 Mar; 26(7):. PubMed ID: 33807292 [TBL] [Abstract][Full Text] [Related]
12. Activation and Inactivation of Primary Human Immunodeficiency Virus Envelope Glycoprotein Trimers by CD4-Mimetic Compounds. Madani N; Princiotto AM; Zhao C; Jahanbakhshsefidi F; Mertens M; Herschhorn A; Melillo B; Smith AB; Sodroski J J Virol; 2017 Feb; 91(3):. PubMed ID: 27881646 [TBL] [Abstract][Full Text] [Related]
13. Dissociation of gp120 from HIV-1 virions induced by soluble CD4. Moore JP; McKeating JA; Weiss RA; Sattentau QJ Science; 1990 Nov; 250(4984):1139-42. PubMed ID: 2251501 [TBL] [Abstract][Full Text] [Related]
14. Rational Design of A Novel Small-Molecule HIV-1 Inactivator Targeting Both gp120 and gp41 of HIV-1. Pu J; Dai Y; Wang Q; Lu L; Zhang J; Xu W; Xie L; Wang S; Yu F; He X; Jiang S Front Pharmacol; 2020; 11():613361. PubMed ID: 33569006 [TBL] [Abstract][Full Text] [Related]
15. Development of HIV-1 fusion inhibitors targeting gp41. Lu K; Asyifah MR; Shao F; Zhang D Curr Med Chem; 2014 Jun; 21(17):1976-96. PubMed ID: 24350848 [TBL] [Abstract][Full Text] [Related]
16. N-substituted pyrrole derivatives as novel human immunodeficiency virus type 1 entry inhibitors that interfere with the gp41 six-helix bundle formation and block virus fusion. Jiang S; Lu H; Liu S; Zhao Q; He Y; Debnath AK Antimicrob Agents Chemother; 2004 Nov; 48(11):4349-59. PubMed ID: 15504864 [TBL] [Abstract][Full Text] [Related]
17. An alteration of human immunodeficiency virus gp41 leads to reduced CCR5 dependence and CD4 independence. Taylor BM; Foulke JS; Flinko R; Heredia A; DeVico A; Reitz M J Virol; 2008 Jun; 82(11):5460-71. PubMed ID: 18353949 [TBL] [Abstract][Full Text] [Related]
18. Kinetic factors control efficiencies of cell entry, efficacies of entry inhibitors, and mechanisms of adaptation of human immunodeficiency virus. Platt EJ; Durnin JP; Kabat D J Virol; 2005 Apr; 79(7):4347-56. PubMed ID: 15767435 [TBL] [Abstract][Full Text] [Related]
19. Conformational changes induced in the human immunodeficiency virus envelope glycoprotein by soluble CD4 binding. Sattentau QJ; Moore JP J Exp Med; 1991 Aug; 174(2):407-15. PubMed ID: 1713252 [TBL] [Abstract][Full Text] [Related]
20. Palmitic Acid Is a Novel CD4 Fusion Inhibitor That Blocks HIV Entry and Infection. Lee DY; Lin X; Paskaleva EE; Liu Y; Puttamadappa SS; Thornber C; Drake JR; Habulin M; Shekhtman A; Canki M AIDS Res Hum Retroviruses; 2009 Dec; 25(12):1231-41. PubMed ID: 20001317 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]